OncoExTra (Oncomap™ ExTra) for Metastatic Cancer
Genomic alterations drive tumorigenesis, influencing disease progression, therapeutic response, and recurrence. Comprehensive genomic profiling has become essential for precision oncology. The OncoExTra™ test is a next-generation sequencing (NGS)-based comprehensive assay that evaluates both the whole exome (DNA) and whole transcriptome (RNA). It interrogates over 20,000 genes to detect, including Single nucleotide variants (SNVs), Insertions/deletions (indels), Copy number alterations (amplifications/deletions), Gene fusions and rearrangements, Tumor mutational burden (TMB) and Microsatellite instability (MSI).
The OncoExtra test is recommended for cancer patients with recurrent metastases, refractory disease, or rare cancers. It helps guide critical treatment decisions for cancers of the lung, breast, colon, and bladder. This comprehensive test can uncover important diagnostic and prognostic information that targeted DNA panel testing may miss. The assay also provides actionable insights into potential FDA-approved therapies, clinical trial eligibility, and biomarker-driven therapeutic options.
- Guides treatment selection (e.g., chemotherapy, targeted therapy, immunotherapy)
- Identifies eligibility for biomarker-directed clinical trials
- Predicts metastasis, recurrence risk, and survival outcomes
Results are interpreted in a clinically integrated manner by board-certified molecular pathologists. Key reportable elements include:
- Genomic alterations with potential therapeutic relevance
- Pathogenicity classification (e.g., Tier 1: FDA-approved therapy biomarkers)
- MSI status and TMB level
- Relevant gene fusions
- RNA expression profiles (where applicable)
- Clinical trial matching
Not applicable, interpretive report provided based on detected alterations
Three specimens are required:
- 1. Tumor sample: FFPE, core needle biopsy (overnight shipping on cold pack)
- 2. Matched normal samples: Peripheral blood (3-4mL, EDTA)
- 3. Separate tumor sample for IHC testing
- Oncotarget. 2021;12(8):726-739. [PMID: 33889297]
- Mol Cancer Ther. 2017;16(11):2598-2608. [PMID: 28835386]
- JCO Precis Oncol. 2017 Jul:2017:PO.17.00011. [PMID: 28890946]
- Sci Transl Med. 2015;7(283):283ra53. [PMID: 25877891]
- Exact Sciences OncoExTra Website; https://precisiononcology.exactsciences.com/healthcare-providers/therapy-selection/advanced-solid-tumors/oncoextra